Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Content crawled from ashuklin.com suggests it is a corporate website for a Chinese pharmaceutical company, with businesses spanning innovative antiviral drugs, human-derived proteins, generic formulations, and in-vitro diagnostics. The page repeatedly mentions the STAR Market stock code 688488, the oral anti-HIV innovative drug Aibonde®, human-derived protein online adsorption technology, and multiple production bases in Yangzhou. However, the page title and body also repeatedly contain abnormal gambling-related keywords such as “开云·官方版网站登录入口-开云(中国),” which are unrelated to the pharmaceutical business. This suggests possible website tampering, mirror-site contamination, or SEO hijacking.
The site mainly functions as a corporate presentation and information disclosure portal, with sections such as About Us, Core Competencies, Development History, Product Center, R&D Pipeline, Production Bases, Business Cooperation, Investor Relations, and Human Resources. On the product side, the focus is on the anti-HIV drug ainuoweilin tablets / Aibonde®, with pipeline development around first-line combination therapies. The human-derived protein business emphasizes protein extraction from urine and resin-based online adsorption technology. Generic formulations include senna leaf granules, Changfukang®, and others. The in-vitro diagnostics segment focuses on HIV diagnostic equipment and reagents, supporting its strategy of integrated HIV diagnosis and treatment.
The body text does not provide specific prices for drugs, diagnostic reagents, or CMO services. It only mentions that Aibonde® has been included in China’s National Reimbursement Drug List, meaning patients’ actual out-of-pocket costs may depend on reimbursement negotiations, hospital procurement, regional policies, and prescription channels. Business cooperation, CMO, and general agency arrangements should fall under enterprise-level negotiated pricing.
The main advantage is a clear business focus, especially its positioning in domestic innovative anti-HIV drugs and human-derived protein raw materials. The site discloses R&D projects, production bases, capacity, strategic partnerships, and investor relations information, making it useful for industry partners conducting preliminary research. The drawbacks are also obvious: the content appears outdated, with news concentrated in 2021–2022; the abnormal branding text severely undermines credibility; and there is insufficient information for patients, including medication guidance, drug instructions, compliant purchase channels, and contact details.
The site is better suited to pharmaceutical distribution companies, hospital procurement teams and clinical partners, R&D outsourcing or CMO partners, investors, and pharmaceutical industry researchers. Ordinary patients looking for information on medication use should prioritize consultation with licensed medical institutions and pharmacists rather than relying solely on information from the website.
Judging from the language and business focus, the site is aimed at the Chinese market and should theoretically be directly accessible from China. However, given the presence of abnormal keyword contamination, it is advisable to cross-check its authenticity through listed-company announcements, drug regulator databases, and officially registered corporate domains.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on ashuklin.com official site.
ashuklin.com is an China gambling provider. TG4G tracks its product information, an overall rating of 1.0/10, and a China-accessibility score of Unknown. Click "Visit Official Site" to reach ashuklin.com directly.